Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 10/20 | 0.52 |
| ▸ | KDM1B | Q8NB78 | 3/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.36 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | SLC9A3 | P48764 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL483392 | 0.77 | KDM1A (0.65) | KDM1AKDM1BCYP11B2GRIN2DGRIN3B | |
| SCHEMBL1722308 | 0.71 | GRIN2D (0.41) | KDM1AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL7431326 | 0.71 | GRIN2D (0.41) | KDM1AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL28611238 | 0.69 | KDM1A (0.96) | KDM1AKDM1BCYP11B2 | |
| SCHEMBL29370901 | 0.65 | KDM1A (0.52) | KDM1AKDM1BCYP11B2GRIN2DGRIN3B | |
| SCHEMBL28386740 | 0.65 | KDM1A (0.52) | KDM1AKDM1BCYP11B2 | |
| SCHEMBL7972799 | 0.65 | KDM1A (0.52) | KDM1AKDM1BCYP11B2GRIN2DGRIN3B | |
| SCHEMBL2971882 | 0.65 | GRIN2D (0.36) | KDM1AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL413013 | 0.65 | KDM1A (0.52) | KDM1AKDM1BCYP11B2GRIN2DGRIN3B | |
| SCHEMBL27798092 | 0.65 | GRIN2D (0.36) | KDM1AGRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10711004-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2020-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10711004-B2 | Oxadiazole transient receptor potential channel inhibitors | TRPA1, TRPV1, TRPV3 | KDM1A 3316/4885KDM1B 3420/4885CYP11B2 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.